Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics

Edward A Copelan; Michael R Grunwald; Lawrence J Druhan; Belinda R Avalos

doi:10.1016/j.hemonc.2015.09.003

Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics

Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):143-9. doi: 10.1016/j.hemonc.2015.09.003. Epub 2015 Oct 11.

Authors

Edward A Copelan¹, Michael R Grunwald², Lawrence J Druhan², Belinda R Avalos²

Affiliations

¹ Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA. Electronic address: [email protected].
² Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA.

PMID: 26459077
DOI: 10.1016/j.hemonc.2015.09.003

Abstract

Most patients with acute myeloid leukemia can be induced into complete remission, but postremission treatment is required for cure. The choice of postremission therapy in a majority of nonelderly patients, between intensive chemotherapy and allogeneic hematopoietic cell transplantation, is largely determined by the results of conventional cytogenetic analysis. In 45% of patients with a normal karyotype, the presence or absence of specific molecular mutations should be used to determine the prognosis and postremission treatment. In addition, the identification of mutations may indicate a role for targeted intervention, including following transplantation.

Keywords: Acute myeloid leukemia; Cytogenetics; Molecular markers.

Publication types

Review

MeSH terms

Biomarkers, Tumor / genetics*
Cytogenetic Analysis*
Humans
Karyotyping
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / therapy*
Mutation / genetics
Remission Induction

Substances

Biomarkers, Tumor